Bret Jensen, Seeking Alpha

Bret Jensen

Seeking Alpha

Miami Beach, FL, United States

Contact Bret

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

  • Unknown
  • Seeking Alpha
  • TheStreet

Past articles by Bret:

When There Is One Cockroach

Equities cratered late in the week as Silicon Valley Bank collapsed. Here is my strategy in light of the SIVB situation. → Read More

Centene: A 'Check Down' Play (NYSE:CNC)

Centene Corporation shares are down a third from their all-time high set in August 2022. Click here to see why CNC stock is a Hold. → Read More

Repare Therapeutics: What Roche And Bristol-Myers Squibb See (NASDAQ:RPTX)

Repare Therapeutics has significant collaboration deals with drug giants Roche and Bristol-Myers Squibb. Read more to see an investment analysis of RPTX stock. → Read More

Align Technology: Valuation Not 'Aligned' To Current Growth Prospects (NASDAQ:ALGN)

Align Technology's shares have doubled off their November 2022 low. Click here to see why ALGN stock is an avoid now. → Read More

ProPhase Labs: Lots Of Moving Pieces (NASDAQ:PRPH)

ProPhase Labs has seen huge revenue growth from Covid testing but is rapidly diversifying into other areas. Click here to see our take on PRPH stock. → Read More

Citius Pharmaceuticals: Balanced Risk-Reward Bet, Near-Term Catalysts (NASDAQ:CTXR)

Citius Pharmaceuticals' shares should see volatility in the ensuing months as all three of the company’s clinical programs provide catalysts. Find out why CTXR stock is a Hold. → Read More

Prometheus Biosciences: Profit Taking Lurking Ahead (NASDAQ:RXDX)

Prometheus Biosciences stock has tripled since positive mid-stage trial results for its primary candidate. Click here to see our take on RXDX stock. → Read More

Beam Therapeutics Stock: An Upgraded View (NASDAQ:BEAM)

Beam Therapeutics develops precision genetic medicines for patients suffering from serious diseases in the US. Click here to read my analysis of BEAM stock. → Read More

Sana Biotechnology: Burning Cash, Going Nowhere Fast (NASDAQ:SANA)

Today, we take our first look at Sana Biotechnology, a clinical-stage developmental company. Read more here. → Read More

Fulgent Genetics: Surviving The Covid Cliff (NASDAQ:FLGT)

Fulgent continues to manage through a huge drop off in Covid testing revenues as the pandemic ebbs. Read more to see a full investment analysis of FLGT stock. → Read More

GlycoMimetics (GLYC): Unraveling The Tea Leaves

We take a look at small biopharma concern called GlycoMimetics that's focused on developing treatments for disease through inhibition of subset of proteins called selectins. Read more here. → Read More

Exact Sciences Corporation: Fully Priced After Big Rally (NASDAQ:EXAS)

Exact Sciences stock has soared 35% so far in 2023 thanks largely to an upward revision to Q4 guidance. Click here to see our take on EXAS stock. → Read More

The Prognosis For Protalix BioTherapeutics Stock (NYSE:PLX)

Protalix BioTherapeutics has rallied after its Fabry disease asset PLX-102 received a PDUFA date from the FDA. Here's a full investment analysis on PLX stock. → Read More

Mirati Therapeutics: Suddenly A Battleground Stock (NASDAQ:MRTX)

Mirati Therapeutics is focused on developing product candidates to address the genetic and immunological promoters of cancer. Read my analysis of MRTX stock. → Read More

Kodiak Sciences (KOD): A Chance To Change The Narrative

Kodiak stock was crushed last Feb. when its lead developmental asset failed to meet its primary end point. Check out if KOD stock is now worthy of a small bet. → Read More

Seres Therapeutics: FDA Approval Straight Ahead (NASDAQ:MCRB)

Today, we take a look at microbiome therapeutic developer Seres Therapeutics. It appears headed to its first FDA approval. Click here for our take on MCRB. → Read More

Annovis Bio: Moving Forward Against Parkinson's (NYSE:ANVS)

Annovis Bio is advancing its primary drug candidate into late-stage development to potentially treat both Alzheimer's and Parkinson's disease. Find out why ANVS stock is a Hold. → Read More

Cidara Therapeutics: FDA Approval Dead Ahead (NASDAQ:CDTX)

Cidara has an impressive set of collaboration deals with larger drug firms and its first FDA approval is on the near-term horizon. See why I'm bullish on CDTX stock. → Read More

Diving Into Design Therapeutics Stock (NASDAQ:DSGN)

Design Therapeutics is an early clinical-stage biopharmaceutical concern. Read more to see my thoughts on DSGN and my recommendation. → Read More

Immutep: A Worthy $2 Dart Throw (NASDAQ:IMMP)

Today, we revisit a small cap oncology concern called Immutep for the first time in two years. Read my investment analysis of IMMP stock. → Read More